Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity (pages 1930–1940)
Dr. Craig A. Coburn, Dr. Peter T. Meinke, Wei Chang, Dr. Christine M. Fandozzi, Donald J. Graham, Dr. Bin Hu, Qian Huang, Dr. Stacia Kargman, Dr. Joseph Kozlowski, Dr. Rong Liu, Dr. John A. McCauley, Dr. Amin A. Nomeir, Dr. Richard M. Soll, Dr. Joseph P. Vacca, Dr. Dahai Wang, Dr. Hao Wu, Dr. Bin Zhong, Dr. David B. Olsen and Dr. Steven W. Ludmerer
Version of Record online: 14 OCT 2013 | DOI: 10.1002/cmdc.201300343
Effective treatment of chronic hepatitis C with direct-acting antivirals will require combination therapy with multiple agents that target different steps in the viral replication cycle and impose a high barrier to resistance. MK-8742 is a potent inhibitor of hepatitis C virus non-structural protein 5A (HCV NS5A) that is being developed as a component of an once-daily, all-oral, interferon-free regimen for the treatment of chronic HCV infection.